Jan 30 2012
In this post in the PLoS "Speaking of Medicine" blog, guest blogger Christian Lienhardt, senior scientific adviser at the Stop TB Partnership and WHO, "discusses the International Roadmap for Tuberculosis (TB) Research, a framework outlining priority areas for investment in TB research." He writes, "The tools available for TB control are old, lack effectiveness, and are not readily accessible in many settings," adding, "Fortunately there is hope, thanks to notable progress in the development of new tools for TB control over the last decade," such as "the recent introduction of Xpert MTB/RIF -- a DNA-based molecular assay that can diagnose TB and the presence of rifampicin-resistance in 100 minutes" (1/26).
This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente. |